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Background: Although described in several reports, imported malaria in Europe has not been surveyed nationwide
with overall coverage of patients and individually rechecked background information. Plasmodium falciparum
infections have been reported despite regularly taken appropriate chemoprophylaxis, yet the reliability of such
questionnaire-based retrospective data has been questioned. This was the starting-point for conducting a
prospective nationwide survey of imported malaria where compliance data was double-checked.
Methods: Data was collected on all cases of imported malaria confirmed and recorded by the reference laboratory
of Finland (population 5.4 million) from 2003 to 2011, and these were compared with those reported to the
National Infectious Disease Register (NIDR). Background information was gathered by detailed questionnaires sent
to the clinicians upon diagnosis; missing data were enquired by telephone of clinician or patient. Special attention
was paid to compliance with chemoprophylaxis: self-reported use of anti-malarials was rechecked for all cases of
P. falciparum.
Results: A total of 265 malaria cases (average annual incidence rate 0.5/100,000 population) had been recorded by
the reference laboratory, all of them also reported to NIDR: 54% were born in malaria-endemic countries; 86% were
currently living in non-endemic regions. Malaria was mainly (81%) contracted in sub-Saharan Africa. Plasmodium
falciparum proved to be the most common species (72%). Immigrants constituted the largest group of travellers
(44%). Pre-travel advice was received by 20% of those born in endemic regions and 81% of those from
non-endemic regions. Of those with P. falciparum, 4% reported regular use of appropriate chemoprophylaxis
(mefloquine or atovaquone/proguanil or doxycycline for regions with chloroquine-resistant and atovaquone/
proguanil or doxycycline for regions with mefloquine-resistant P. falciparum); after individual rechecking, however, it
was found that none of them had been fully compliant.
Conclusions: Information on compliance with chemoprophylactic regimen cannot be relied on, and it should be
rechecked if malaria is suspected. The results of the present study suggest that mefloquine, atovaquone/proguanil
and doxycycline are effective as chemoprophylaxis against P. falciparum malaria, when taken conscientiously.
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Malaria continues to be a major public health problem
with over 200 million infections and approximately
655,000 deaths worldwide, 90% occurring in Africa [1].
The annual number of notified malaria cases imported
into European countries has been 10,000–13,000 (2-3/
100,000 population) [2,3] in previous years. In 2010, the
World Health Organization (WHO) reported 6,244 cases
of imported malaria in Europe [4], which is considered
an underestimation [5]. Several studies deal with data
solely from single European hospitals, cities, areas [6-9]
and networks [10,11]. For most of them, and for a num-
ber of recent large reports containing national malaria
surveillance data from Europe [12-16], merely limited
background information has been collected or significant
parts of pertinent data are missing. In all these surveys,
the reliability of information collected by questionnaires
has been highlighted as a problem. Despite appropriate
chemoprophylaxis, cases of Plasmodium falciparum
malaria have been reported. However, the use of anti-
malarial drugs has been recorded retrospectively solely
on the basis of questionnaires [13,15,17,18], without
reconfirming regimen compliance.
The research group set out to prospectively collect
and survey detailed data on all Finnish travellers with
malaria, placing emphasis on compliance with chemo-
prophylaxis. The surveillance of imported malaria as
well as travel trends and anti-malarial drug sales in
Finland 1995-2008 has been discussed in an overview
published earlier [19]. It showed that the number of trips
to malaria-endemic areas increased during 2000-2008.
Most infections were acquired in the same geographical
regions as the immigrants’ country of birth. Another im-
portant finding was that travel advice is not getting
through to immigrants visiting their friends and relatives
(VFR) [19].
Malaria prophylaxis and treatment should be fairly uni-
form throughout Finland because of well-known national
guidelines. The instructions for malaria prophylaxis are
available for both health care professionals and the public
in Matkailijan terveysopas (travellers’ health guide) [20]
(first published in 1993) freely accessible and up-to-date
on the National Institute for Health and Welfare (THL)
website [21]. National guidelines for malaria diagnostics
and treatment are presented in Akuuttihoito-opas (manual
of emergency treatment) [22,23] continuously updated
and available online for Finnish physicians.
Detailed background information was collected on
imported malaria cases in Finland during 2003–2011 in
order to identify risk groups, and to obtain information
on both the use of chemoprophylaxis and adherence to
the national guidelines. Of particular interest in the
study was the question whether P. falciparum malaria
can indeed be contracted in spite of appropriatechemoprophylaxis. To that end individual compliance
data was rechecked from the clinician or the patient in
all P. falciparum cases.Methods
Surveillance of malaria in Finland
The National Infectious Disease Register (NIDR) was
established, and malaria became a notifiable disease in
Finland in 1995. Since then, all Finnish clinical micro-
biology laboratories conducting malaria diagnostics have
reported positive tests to the NIDR. In addition, surveil-
lance data have been collected from clinicians to the
NIDR by a notification form, which covers such variables
as age, sex, country of birth, diagnostic specimen date,
and country of infection.
HUSLAB is the national reference laboratory where
positive malaria slides from all Finnish laboratories are
delivered for confirmation. In cases of unclear species
identification, HUSLAB has, since the beginning of
2004, sent malaria smears over to the Swiss Tropical In-
stitute for further affirmation with the polymerase chain
reaction (PCR).Study design
For the present study, a case was defined as a person
with Plasmodium infection confirmed by microscopy.
Immediately after diagnosis HUSLAB sent detailed ques-
tionnaires to clinicians treating patients confirmed as
malaria cases. The replies were forwarded to the author
HS, who without delay rechecked and filled in any miss-
ing details from the patient records of those treated at
the Helsinki University Central Hospital (HUCH), and
consulted the clinicians, if the answers were found un-
clear or incomplete. If the clinicians were not able to
provide the information needed, HS got in touch with
the individual patients over the telephone. Data about
compliance with prophylactic regimen was rechecked in
all P. falciparum cases if the information was incomplete
and, especially, if regular use of chemoprophylaxis was
reported. The data obtained were consistently compared
with the NIDR notifications, and used for the annual re-
ports to the THL and the WHO.
The data comprised demographic variables (sex, age,
country of birth, nationality, recent and previous coun-
tries of residence, date of immigration), accurate travel
history (countries and areas visited plus dates and reason
for travel), pre-travel advice received; use of chemo-
prophylaxis, description of symptoms, dates of onset,
first contact with healthcare and presenting at hospital,
diagnostic specimen date, malaria species, diagnostic
method, date of commencing treatment, medication
used, time and place of diagnosis, treatment and hospi-
talisation, as well as disease complications and outcome.
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open question in the questionnaire, and were analysed
only for patients treated at the HUCH, as their data
could be obtained systematically from patient records
throughout the study period.
Ethics statement
The study protocol was approved by the Department of
Internal Medicine of the Helsinki University Central
Hospital. Background information was collected by the
reference laboratory as part of its monitoring activity.
Definitions
The travellers were grouped according to the reason for
travel as follows: Finnish resident travelling for tourism,
Finnish resident travelling for work or education, ex-
patriate, visiting friends and relatives, recently arrived
immigrant (immigrant having not visited the country of
origin or other malaria-endemic areas after immigration)
and foreign visitor.
Countries of birth and countries where the infection
was contracted were grouped as follows: sub-Saharan
Africa, Southeast Asia, Central Asia and the Indian sub-
continent, South and Central America and the Caribbean,
North Africa, West Asia, Northeast Asia and Oceania, as
modified from GeoSentinel [24]. In cases where a number
of countries had been visited, the most probable country
of contracting the infection was determined individually,
looking at travel history and incidence of malaria in the
regions visited.
Chemoprophylaxis was considered appropriate if it
followed the national guidelines valid at the time of travel:
mefloquine or atovaquone/proguanil or doxycycline for
regions where P. falciparum malaria is chloroquine-
resistant, and atovaquone/proguanil or doxycycline for re-
gions where it is mefloquine-resistant.
Statistics
Differences between the various groups were tested
using the chi-square test, student’s t-test or Mann-
Whitney U-test, as appropriate. Statistical analyses were
carried out with SPSS version 19.0 (Norusis; SPSS Inc.,
Chicago Illinois, USA).
Results
General characteristics
Data on a total of 265 imported malaria cases were
recorded between 2003 and 2011 both by the reference
laboratory and the NIDR (range, 21-40/year; average an-
nual incidence rate, 0.5/100,000 population); the indivi-
dual cases were checked and found to match in both
sets of data. For the present study, detailed information
about the patients was gathered solely from question-
naires in 36%, from questionnaires and original patientrecords in 48%, and, in addition to these, by contacting
the clinician or the patient in 16% of the cases.
Table 1 presents the characteristics and data for all pa-
tients divided according to the malaria endemicity of
their countries of birth. Of all cases, 55% were foreign-
born, 45% were native Finns. Among those of foreign
origin, 99% (144/146) were born in malaria-endemic re-
gions, 86% (126/146) in sub-Saharan Africa. There were
25 (9%) under 18 years of age, 88% (22/25) of them born
in a malaria-endemic regions, and 60% (15/25) recently
immigrated into Finland. The patients originally coming
from regions where malaria is endemic were younger
(p=<0.001) and more often male (76% vs 64%, p=0.016)
than those born in Finland or other non-endemic coun-
tries. No difference was found in the duration of travel
between the two groups (median 35 vs 32 days, p=0.83).
The number of imported malaria cases varied between
21 and 40 per year (Figure 1). The most common species
was P. falciparum (72%, 190/265 cases, including four
double infections with other Plasmodium species),
followed by single infections of Plasmodium vivax (19%,
51/265), Plasmodium ovale (6%, 15/265), Plasmodium
malariae (2%, 6/265), and Plasmodium knowlesi (one
case). In two cases the species remained unidentified. The
majority of all infections (81%) and most of P. falciparum
cases (96%) came from sub-Saharan Africa (Table 2). The
countries where the disease was most commonly
contracted were Nigeria (n=39 cases), Cameroon (n=23),
the Gambia (n=23), Ghana (n=21), India (n=19), and
Sierra Leone (n=16).
Pre-travel advice and use of prophylaxis
Leaving out 39 recently arrived immigrants, pre-travel
advice was received by 49% (102/209) of the cases; 20%
(19/97) of those born in endemic, and 81% (83/102) of
those born in non-endemic regions (p<0.001) (Table 1).
Pre-travel advice and anti-malarial drug compliance are
presented in Table 3, grouped according to reason for
travel.
Most of the cases (68%) used no chemoprophylaxis; 23%
did not take their anti-malarials according to prescription
(40% took the drugs irregularly, 27% discontinued the
chemoprophylaxis during the trip and 33% withdrew it
prematurely after returning from malaria-endemic area);
9% adhered to the dosage and frequency prescribed, but
46% of them were given an inappropriate drug. Regular
use of appropriate prophylaxis was reported for 5% (13/
262) of all cases: for 13 of the 121 natives of non-endemic
countries, but for none of the 144 originating from
malaria-endemic regions (11% vs 0%, p<0.001) (Table 1).
Of those with P. falciparum malaria, 73% (138/190) had
taken no chemoprophylaxis and 27% (50/190) either took
appropriate drugs but did not take them according to pre-
scription (n=25; 44% took the drugs irregularly, 36%
Table 1 Patient characteristics and data by region of birth
Characteristics of malaria cases Total Born in malaria-
endemic area
Born in Finland or other
non-endemic area
Number of travellers 265 144 (54%) 121 (46%)
Age in years, median (range) 31(1-71) 29 (1-71) 37 (0-71)
Sex (male) 187(71%) 110 (76%) 77 (64%)
Country of residence Malaria-endemic area 36(14%) 22 (15%) 14 (12%)
Finland or other
non-endemic area
229(86%) 122 (85%) 107 (88%)
Duration of travel in days1, median (IQR)2 33(16-92) 32 (23-68) 35 (14-151)
Geographic region where malaria was contracted Sub-Saharan Africa 214(81%) 126 (88%) 88 (73%)
Central Asia and Indian
subcontinent
19 (7%) 7 (5%) 12 (10%)
Southeast Asia 18 (7%) 7 (5%) 11 (9%)
South and Central America
and Caribbean
8 (3%) 1 7 (6%)
Other (North Africa, Oceania) 6 (2%) 3 (2%) 3 (2%)
Reason for travel Visiting friends and relatives 78 (29%) 76 (53%) 2 (2%) 3
Finnish resident, tourism 66 (25%) 2 (1%) 64 (53%)
Recently arrived immigrant 39 (15%) 38 (26%)4 1 (1%)
Foreign visitor 28 (11%) 23 (16%) 5 (4%)
Expatriate 28 (11%) 2 (1%) 26 (21%)
Finnish resident, work/
education
26 (10%) 3 (2%) 23 (19%)
Received pre-travel advice5 102/209
(49%)
19/97 (20%) 83/112 (81%)
Used appropriate chemoprophylaxis regularly6 13 (5%) 0 13 (11%)
Onset of symptoms after leaving malaria-endemic area
in days7, median (IQR)2
6 (1-15) 3 (1-13) 8 (2-19)
Duration of symptoms before first contact with
healthcare in days8, median (IQR)2
3 (1-5) 3 (1-5) 2.5 (1-4)
1 Data missing for 32 cases, 39 recently arrived immigrants excluded.
2 Interquartile range.
3 Children of immigrant family.
4 Includes four adopted children.
5 Data missing for 17 cases; 39 recently arrived immigrants excluded.
6 Data missing for three cases.
7 Data missing for 19 cases.
8 Data missing for 15 cases; four had no symptoms.
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drew it prematurely after returning from malaria-endemic
area) or did not take appropriate drugs (n=25; 44% took
them according to prescription, 20% irregularly, 8%
discontinued the prophylaxis while travelling and 28%
withdrew it prematurely after the trip). Notably, 36% (63/
175, data missing for 15 cases) of the patients with
P. falciparum malaria reported having received pre-
travel advice. Appropriate regular chemoprophylaxis
was reported by 4% (8/190) in the questionnaires. After
double-checking this information, it was found that
none of the patients had been fully compliant (Table 4).
As to other Plasmodium species, there were 12 cases
infected with P. vivax or with P. ovale, who werereported to have conscientiously used adequate anti-
malarials; these cases may be explained by a reactivation
of dormant liver hypnozoites. One patient had con-
tracted P. malariae in spite of regular prophylaxis
(Table 4).
Symptoms and patients’ delay
With respect to the time span between departure from a
malaria region and onset of symptoms, those born in en-
demic areas differed from those born in non-endemic
areas (3 days vs 8 days, respectively; p=0.005) (Table 1).
Four patients had no symptoms. Three of them were
asymptomatic pregnant immigrants examined because
of anaemia [25]. One was a refugee child whose siblings
Figure 1 Annual number of malaria cases diagnosed in Finland by species.
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gametocytes and was not treated. No difference was
found in the duration of symptoms before initial contact
with healthcare between those born or not born in
malaria-endemic regions (median 3 vs 2.5 days, respect-
ively, p=0.493 (Table 1).Treatment and outcome
The time span from the first contact with healthcare to
diagnosis was one day or shorter for 78% (201/259) of
patients, and from presenting at hospital to diagnosis
one day or shorter for 97% (254/262). After the diagno-
sis, specific anti-malarial treatment was started within
one day in 98% of the cases (256/261).
Most of the patients (99%, 261/265) were treated in
hospital; 96% (250/261) as in-patients. The median
length of hospital stays was five days (IQR 3-7, data
missing for 17 cases). Before the year 2010, the period of
hospitalization was significantly longer than during
2010-2011 (median 5 days vs 3.5 days, p=0.001).
Information about the treatment was available in 98%
(261/265) of the cases. The first drug used for treatment
was oral quinine for 48% of the patients, intravenous
quinine for 20%, artemether/lumefantrine for 12%,Table 2 Malaria cases by species and geographic region of ac
Geographic region P. falciparum P. vivax
Sub-Saharan Africa 182* 10
Central Asia and Indian subcontinent 3 16
Southeast Asia 2** 15
South and Central America and Caribbean 2 6
Oceania 1 4
North Africa 0 0
Total 190 51
* Includes three double infections: one P. falciparum + P. vivax, one P. falciparum +
** Includes one double infection: P. falciparum + P. vivax.intravenous artesunate for 10%, chloroquine for 5% (not
used in P. falciparum infections), mefloquine for 4%,
and atovaquone/proguanil for 1%. All those who re-
ceived doxycyclin were also prescribed quinine or
artesunate.
Complications were only recorded for the patients
treated at the HUCH (n=131): 8% of them had compli-
cations; 3% (3/93) of those born in malaria-endemic re-
gions and 21% (8/38) of those born in non-endemic
regions (p=0.001). One patient with severe complicated
P. falciparum malaria was resuscitated because of heart
arrest, and was left with a permanent brain damage.
There were no deaths.Discussion
This is presumably the first study to survey comprehen-
sive nationwide data on imported malaria infections, and
to double-check background information initially obtained
by questionnaires. While several studies have reported
malaria cases in patients taking appropriate chemo-
prophylaxis [13,15,17,18], compliance has proved difficult
to assess, which prompts the question, whether there ex-
ists significant clinical resistance to the drugs currently
used in chemoprophylaxis. In the present survey thequiring the infection
P. ovale P. malariae P. knowlesi Unidentified species Total
14 6 0 2 214
0 0 0 0 19
0 0 1 0 18
0 0 0 0 8
0 0 0 0 5
1 0 0 0 1
15 6 1 2 265
P. ovale and one P. falciparum + P. malariae.
Table 3 Pre-travel advice and use of chemoprophylaxis by reason for travel
Reason of travel Pre-travel
advice
received1
Use of chemoprophylaxis2 Chemoprophylaxis
appropriate +
taken regularly
according to
prescription3
No chemoprophylaxis Taken, but not
regularly
Taken regularly
according to prescription
Finnish resident, tourism 41 (66%) 32 (49%) 20 (30%) 14 (21%) 6 (9%)
Finnish resident, work/education 19 (76%) 10 (39%) 11 (42%) 5 (19%) 4 (15%)
Visiting friends and relatives 17 (24%) 61 (78%) 16 (21%) 1 (1%) 0
Recently arrived immigrant 0 39 (100%) 0 0 0
Foreign visitor 3 (12%) 25 (93%) 2 (7%) 0 0
Expatriate 22 (82%) 12 (44%) 11 (41%) 4 (15%) 3 (11%)
Total 102 (41%) 179 (68%) 60 (23%) 24 (9%) 13 (5%)
1Data missing for 17/265 cases.
2Data missing for 2/265 cases.
3Data missing for 3/265 cases.
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cases were contracted despite proper chemoprophylaxis,
yet rechecking individual use of anti-malarials revealed
lacking compliance for all of these cases.
Potential under-reporting or under-diagnosing
Malaria is a notifiable disease in most European coun-
tries, but under-reporting of imported cases may exist
[2,15]. The present study suggests that this does not
apply to Finland: when NIDR information based on noti-
fications from laboratories and clinicians was compared
annually with data collected by the reference laboratory,
it was found that the same individual cases have been
identified in both. Therefore, the data presented here
can aptly be considered to cover all imported malaria
cases diagnosed. Its reliability is further confirmed by
the fact that all the background information was
checked and completed by the same specialist each year.
Finnish residents diagnosed and treated for malaria
abroad are not included in the data.Table 4 Use of chemoprophylaxis by malaria species
Chemoprophylaxis Plasmodium falciparum
No chemoprophylaxis 138
Chemoprophylaxis taken Appropriate chemoprophylaxis and full
compliance (rechecked)
no yes
Mefloquine 17 0
Atovaquone/proguanil 4 0
Doxycycline 4 0
Chloroquine 11 0
Chloroquine + proguanil 4 0
Other 10 0
Missing information 2
Total 190 0Although it appears that diagnosed cases are not being
under-reported, diagnoses might still be missed. This
concerns recently arrived immigrants in particular: while
malaria among non-immune travellers is characterized
by fever and various other symptoms, many studies re-
port asymptomatic, persistent P. falciparum parasit-
aemia in immigrants from highly endemic regions even
years after immigration [26-29]. In pregnant immigrants,
the only symptom can be anaemia [25].
General characteristics
The annual numbers of imported malaria cases in-
creased during the study period – as in most other
European countries [5] – which reflects increased travel
to malaria-endemic countries [19], yet regions and risk
groups remained the same. There was a peak in the
number of cases in 2008 due to a cluster of Finnish trav-
ellers to the Gambia [30]. Distribution of the patients’ age
and gender, malaria species, duration of travel, geographical
regions where malaria was contracted, and risk groupsOther malaria species Total
41 179
Appropriate chemoprophylaxis, drugs reported to be
taken conscientiously
no yes
6 11 34
4 1 9
2 0 6
6 1 18
0 0 4
2 0 12
1 3
62 13 265
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Consistent with other studies [6-10,12-15,31], the most com-
mon species were P. falciparum and P. vivax. Plasmodium
falciparum infections were mainly acquired in sub-Saharan
Africa, and most of P. vivax infections on the Indian subcon-
tinent and in Southeast Asia. A case of P. knowlesi was diag-
nosed in a Finnish traveller to mainland Malaysia in 2007
[32]. Notably, Asia is the tropical area most favoured by
Finns; Thailand draws more Finnish tourists than the entire
African continent [19]. The fact that most malaria cases are
acquired in sub-Saharan Africa correlates with the risk of
contracting malaria being highest in this region [1].
Even if the majority of travellers to tropical areas are of
Finnish origin, most of the patients with malaria were im-
migrants: 29% VFR and 15% recently arrived immigrants.
The high proportion of VFRs has also been reported in
several previous studies [6,7,9,10,12,13,15,31]. Notably, the
proportion of recently immigrated individuals among mal-
aria patients was high with regard to the relatively low
total number of immigrants to Finland (5% of the citizens
are born abroad [33]), indicating that clinicians should
have a high level of suspicion for malaria when treating
immigrants from endemic regions, especially sub-Saharan
Africa.
Pre-travel advice and use of chemoprophylaxis
Pre-travel advice was received less often by VFRs than
Finnish tourists and residents travelling for work or edu-
cation. None of the VFRs used appropriate chemoprophy-
laxis regularly. Poor adherence has been suggested to be
due to lacking knowledge of malaria transmission and pre-
vention [34], believing that malaria is a minor illness, erro-
neous trust in livelong immunity, and the relatively high
cost of prophylaxis [12,15]. All these data indicate that
more effort should be focused on reaching immigrants
planning to visit friends and relatives.
Of those diagnosed with P. falciparum malaria, none had
taken appropriate chemoprophylaxis conscientiously, yet
one third reported having received pre-travel advice. In
Finland, all drugs used for malaria prophylaxis require pre-
scription by a doctor (chloroquine only since 2006). Des-
pite the fact that national guidelines are easily available, in
five cases the doctor had incorrectly advised against the
use of chemoprophylaxis. Moreover, of the 28 cases where
inappropriate chemoprophylaxis was used, 19 had taken
drugs prescribed by a doctor. This highlights the import-
ance of further training for healthcare professionals. In
nine cases inappropriate drugs had been bought over the
counter at the destination. Pre-travel advice should
emphasize the dangers of such drugs, as resorting to them
may involve a risk of being given both inappropriate
chemoprophylaxis and counterfeit drugs [35]. Media publi-
city caused by the malaria outbreak among Finnish travel-
lers in the Gambia in 2008 may, at least temporarily, haveincreased awareness of risk and prevention of malaria
among the public and medical practitioners alike. The data
contained no patients who had used chloroquine for
chemoprophylaxis in Africa since 2008.
In the present study 4% of those with P. falciparum mal-
aria had reportedly taken appropriate chemoprophylaxis,
but individual rechecking revealed that none of them had
complied with the regimen prescribed. Previous reports
have stated that adherence to chemoprophylaxis is diffi-
cult to assess in data based on questionnaires only
[10,12,13,15]. The present investigation demonstrates that
compliance recorded by means of questionnaires cannot
be relied on, but should be rechecked in all cases of mal-
aria. Histories given by patients who are acutely ill may
not be reliable; clinicians may not have asked sufficiently
detailed questions about the use of prophylaxis before,
during and after the trip; the patients might not be willing
to reveal their poor adherence to the instructions; or they
may have misunderstood them. The last point could ex-
plain why the 17 patients who had conscientiously ad-
hered to their chemoprophylaxis before and during the
trip gave it up immediately after returning from malaria
regions. Taken together, the results of the present study
suggest that mefloquine, atovaquone/proguanil and doxy-
cycline continue to be effective against chloroquine-
resistant P. falciparum malaria, when used regularly.
Symptoms and patients’ delay
The time span between leaving a malaria region and the
onset of symptoms was longer among those born in
non-endemic than those born in endemic countries.
This could reflect the fact that a higher proportion of
those in the first group had used chemoprophylaxis:
while not preventing the disease, non-appropriate
chemoprophylaxis may have delayed the onset of symp-
toms. There was no difference in the duration of symp-
toms before the first contact with healthcare between
the groups; 41% of all cases presented later than three
days after the onset of symptoms, consistently with a
Scottish study [15].
Treatment and outcome
There was no doctors’ delay from the presentation at
hospital to diagnosis or starting specific anti-malarial
treatment after diagnosis. It thus seems that Finnish
doctors working at hospitals are familiar with the guide-
lines and naturally suspect malaria in febrile returning
travellers. By contrast, some improvement could be
expected from those working in primary healthcare: in
22% of cases, the delay from the first contact with
healthcare to diagnosis was more than one day.
Most (95%) of those with malaria were treated as in-
patients; this proportion is higher than reported from
other centres (16-78%) [8-10]. In Europe the national
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spect [5]. In the Finnish guidelines it is recommended that
malaria patients should be treated primarily as in-patients.
The median length of hospital stay was five days, which
accords with other surveys [10]. Notably, the treatment
guidelines were changed over the study period, which was
reflected in the length of hospitalization. According to the
recommendations that came into effect in 2008, compli-
cated P. falciparum malaria should be treated with intra-
venous artesunate instead of intravenous quinine plus
doxycycline, and since 2010 oral artemether/lumefantrine
has been recommended for uncomplicated malaria, in-
stead of oral quinine plus doxycycline. After the latter
change, the length of hospital stays has shortened to four
days in 2010, and further to three days in 2011.
Consistent with other reports [16,26,36], those born in
malaria-endemic regions had fewer complications than
those from non-endemic countries, which is probably
due to the persistence of some degree of acquired im-
munity in these patients. There were no malaria-related
deaths during the study period, perhaps due to the small
number of patients; other studies have reported case fa-
tality rates between 0.4–0.7% [12,13,36].
Conclusions
Compliance with anti-malarial chemoprophylaxis should
always be double-checked, if the disease is suspected. The
data show that mefloquine, atovaquone/proguanil and
doxycycline are still effective in chemoprophylaxis against
P. falciparum malaria, when taken conscientiously.
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